Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey
Abstract Background Current evidence supports the use of NfL as a biomarker for neuroaxonal damage in multiple sclerosis (MS), but translation from clinical trials to clinical practice is needed to guide optimal patient management. Methods The SUNLIT survey, led by the Novartis medical science liais...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2025-12-01
|
| Saila: | BMC Neurology |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12883-025-04547-0 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|